Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC)

Purpose Optimal primary febrile neutropenia(FN) prophylaxis (i.e. ciprofloxacinor granulocyte-colony stimulating factors[G-CSF]) for patients receiving docetaxel- cyclophosphamide(TC) chemotherapy is unknown. We assessed the feasibility of using a novel pragmatic comparative effectiveness trial to compare these standard-of-care options.